Alumis delivered the highest reported PASI 100, meaning complete skin clearance, among oral therapies for plaque psoriasis on August 10, 2026, with 54% of patients reaching that threshold after 48 weeks of continuous treatment with envudeucitinib, the company's lead oral TYK2 inhibitor. The readout from the ONWARD3 long-term extension study, the 48-week follow-on to the pivotal ONWARD1 and ONWARD2 Phase 3 trials, sets up a fourth-quarter 2026 New Drug Application submission to the FDA and a likely first-half 2027 launch. The equity is trading at $25.55, up roughly 470% from a 52-week low of $3.76 and within striking distance of its 52-week high of $31.35, reflecting a market that has already begun to price a credible oral challenger to Bristol-Myers Squibb's deucravacitinib (Sotyktu), which is the only currently approved allosteric TYK2 inhibitor.
The single most important point, in our view, is that the 54% PASI 100 number matters less as a clinical data point than as a commercial positioning event. PASI 100 is the highest hurdle in the psoriasis efficacy ladder, and the only injectable that beats it consistently is the IL-23 class led by Johnson & Johnson's Tremfya and AbbVie's Skyrizi, with each carrying U.S. list prices above $80,000 per patient per year. An oral that gets within 10 to 15 percentage points of those numbers, with the convenience of a pill, has a defensible commercial thesis in a market that exceeded $25 billion globally in 2025. We read the long-term durability data, with approximately 80% of patients who entered ONWARD3 already at PASI 100 maintaining that response, as the second-order finding that institutional investors are most likely to focus on, because durability is what determines real-world persistence and therefore revenue trajectory.
The load-bearing risk is execution, not biology. Alumis reported $93.1 million of net loss in the first quarter of 2026 against $569.6 million of cash and marketable securities, which is a runway of roughly six quarters at the current burn rate of $87 million per quarter in operating cash outflow, but that math assumes no commercial launch spend, no further business development, and no expansion of the pipeline. The next data point that tests the thesis is the topline readout from the LUMUS Phase 2b trial of envudeucitinib in systemic lupus erythematosus, expected in the third quarter of 2026, because lupus is the indication that would most clearly demonstrate the "pipeline-in-a-pill" thesis management has been selling since the May 2025 ACELYRIN merger. A miss there would compress the equity meaningfully; a clean miss-free readout would extend the runway narrative by another twelve months.